alk-in-1

ALK-IN-1 is a Brigatinib analog and an ALK inhibitor commonly used in anti-tumor research.

TRK/ALK-IN-1 is a potent dual inhibitor of TRK and ALK, exhibiting good correlation between its enzymatic inhibition and anti-proliferative activities, with IC50 values of 2.2 nM for TRKA, 9.3 nM for ALK WT, and 38 nM for ALK L1196M. It holds potential for cancer research applications.

ALK-IN-12 is a highly potent and orally active inhibitor of anaplastic lymphoma kinase (ALK), demonstrating an exceptional IC50 value of 0.18 nM. Additionally, ALK-IN-12 displays inhibitory activity against insulin-like growth factor 1 receptor (IGF1R) and insulin receptor (InsR), with IC50 values of 20.3 nM and 90.6 nM, respectively. Notably, its antitumor effects have been observed, making it a promising compound for targeted cancer therapy.

ALK-IN-13 is an inhibitor of ALK (anaplastic lymphoma kinase).

ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).

Mps1-IN-1 is a potent, selective, and ATP-competitive inhibitor of Mps1 kinase (IC50: 367 nM).

TD-004 (HC58-111) is an innovative degrader of anaplastic lymphoma kinase (ALK) fusion proteins, effectively promoting the degradation of ALK proteins. It inhibits the growth of ALK fusion-positive cell lines SU-DHL-1 and H3122, and significantly reduces tumor growth in H3122 xenograft models.

ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.

ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.

ALK/HDAC-IN-1 is a dual inhibitor that targets both ALK and HDAC6, demonstrating IC50 values of 16 nM and 1.03 μM, respectively. This compound exhibits anti-tumor activity.

PROTACALK degrader-1 (compound B1) is a PROTACs-based ALK degrader with a DC50 of 26 nM in H3122 EML4-ALK. It is utilized in creating PROTACALK degrader-2, which boasts excellent bioavailability.

ALK ligand-1 is an ALK ligand that can be utilized in the synthesis of PROTACALK degrader-4.

ALK degrader 1 is a potent degrader using hydrophobic tagging technology (HyT), relying on the ubiquitin-proteasome system to degrade EML4-ALK with a DC50 of 0.13 μM. It demonstrates superior ALK degradation and antiproliferative effects in ALK-dependent cell lines, with no significant cytotoxicity in ALK fusion-negative cells. The compound induces G0/G1 cell cycle arrest and promotes apoptosis, efficiently degrades ALK proteins, and blocks key downstream signaling pathways such as STAT3. Additionally, ALK degrader 1 effectively induces EML4-ALK degradation in vivo and is suitable for researching ALK-related diseases.

Ensartinib (X-396) is a potent and orally active dual ALK/MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

ALK-IN-9 (compound 40) is a highly effective ALK inhibitor, demonstrating remarkable inhibitory activity against cell proliferation, with IC50 values of <0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), and KG-1 cell (OP2-FGFR1).

Trk-IN-7 (compound I-6) is a highly potent TRK inhibitor, with IC50 values of 0.25-10 nM for TRKA, TRKB, and TRKC, respectively. It also shows significant inhibition of EML4-ALK (IC50 <15 nM) and ALK mutations G1202R, C1156Y, R1275Q, F1174L, L1197M, and G1269A (IC50 = 5-50 nM) [1].

Trk-IN-10 (Compound 14j) is a highly effective inhibitor of TRK, with an IC50 of 0.86 nM against TrkA and 6.92 nM against TrkA G595R. As an RTK, Trk is a crucial drug target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) demonstrates superior selectivity in inhibiting Trk, potentially reducing toxicity [1].

ALK5-IN-26 (EX-22) is an ALK (Activin receptor-like kinase) inhibitor with an IC50 ≤ 1 nM for ALK5.

PF-06463922 acetate is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against all known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. PF-06463922 is in clinical trials for the treatment of non–small cell lung cancer (NSCLC).

ALK-IN-21 (Compound B10), a proficient ALK inhibitor targeting the ALKG1202R mutation, demonstrates significant inhibitory activity with IC50 values of 4.59 nM against ALK WT, 2.07 nM against ALK L1196M, and 5.95 nM against ALK G1202R. Moreover, ALK-IN-21 effectively suppresses proliferation in ALK-positive Karpas299 and H2228 cells, achieving IC50 values of 0.07 μM. It is applicable for anaplastic large cell lymphoma research [1].

M4K2234 (Compound 26b) is a selective inhibitor of ALK2, displaying IC50 values of 5 nM for ALK2 and 2144 nM for ALK5. As a chemical probe for ALK1 and ALK2 kinases, it is used in mechanistic studies of BMP signaling and in cancer research where dysregulated ALK2 activity is implicated. Its high selectivity profile supports targeted investigations into ALK-mediated pathways.

Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.

ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation. It demonstrates potent inhibition of ALK/EGFR mutants with IC50 values of 4.3 nM for EGFR L858R T790M in H1975 cells and 3.6 nM for EML4-ALK in BaF3 cells. This compound may be applicable in the research of non-small cell lung cancer (NSCLC) [1].

ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells. It effectively suppresses proliferation in H1975, PC9, and Baf3-EML4-ALK cancer cell lines, with IC50s of 0.0034, 0.0065, and 0.0018 μM, respectively [1].